JP2023516235A5 - - Google Patents

Info

Publication number
JP2023516235A5
JP2023516235A5 JP2022529942A JP2022529942A JP2023516235A5 JP 2023516235 A5 JP2023516235 A5 JP 2023516235A5 JP 2022529942 A JP2022529942 A JP 2022529942A JP 2022529942 A JP2022529942 A JP 2022529942A JP 2023516235 A5 JP2023516235 A5 JP 2023516235A5
Authority
JP
Japan
Prior art keywords
alkyl
oxo
decane
diazaspiro
cyclopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022529942A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023516235A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/062890 external-priority patent/WO2021113362A1/en
Publication of JP2023516235A publication Critical patent/JP2023516235A/ja
Publication of JP2023516235A5 publication Critical patent/JP2023516235A5/ja
Pending legal-status Critical Current

Links

JP2022529942A 2019-12-03 2020-12-02 Ｓｓｔｒ５アンタゴニスト Pending JP2023516235A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962943099P 2019-12-03 2019-12-03
US62/943,099 2019-12-03
PCT/US2020/062890 WO2021113362A1 (en) 2019-12-03 2020-12-02 Sstr5 antagonists

Publications (2)

Publication Number Publication Date
JP2023516235A JP2023516235A (ja) 2023-04-19
JP2023516235A5 true JP2023516235A5 (https=) 2023-12-08

Family

ID=76221934

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022529942A Pending JP2023516235A (ja) 2019-12-03 2020-12-02 Ｓｓｔｒ５アンタゴニスト

Country Status (10)

Country Link
US (3) US20230041621A1 (https=)
EP (3) EP4069702A4 (https=)
JP (1) JP2023516235A (https=)
CN (1) CN115380036A (https=)
AR (1) AR120652A1 (https=)
AU (1) AU2020398874A1 (https=)
CA (1) CA3163243A1 (https=)
TW (1) TW202134248A (https=)
UY (1) UY38976A (https=)
WO (3) WO2021113363A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220150270A (ko) 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
CN116789570B (zh) * 2022-03-14 2026-01-27 长沙理工大学 磺酰胺脱氨制备磺酸衍生物的方法
WO2024204277A1 (ja) 2023-03-27 2024-10-03 株式会社スコヒアファーマ 成長ホルモン分泌促進剤
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds
WO2025222008A1 (en) * 2024-04-19 2025-10-23 Eli Lilly And Company Glucagon receptor agonists and their use as therapies
WO2025222000A1 (en) * 2024-04-19 2025-10-23 Eli Lilly And Company Substituted 1,1'-biphenyl compounds as glucagon receptor agonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1458374A2 (en) * 2001-12-14 2004-09-22 Novo Nordisk A/S Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
EP1786815B1 (en) * 2003-09-10 2011-08-24 Virochem Pharma Inc. Spiro compounds and methods for the modulation of chemokine receptor activity
US7709642B2 (en) * 2004-06-25 2010-05-04 Virochem Pharma, Inc. Spirohydantoin compounds and methods for the modulation of chemokine receptor activity
JP2009502786A (ja) * 2005-07-18 2009-01-29 メルク エンド カムパニー インコーポレーテッド アルツハイマー病を治療するためのスピロピペリジンβ−セクレターゼ阻害剤
WO2008019967A2 (en) * 2006-08-15 2008-02-21 F. Hoffmann-La Roche Ag Phenyl, pyridine and quinoline derivatives
US20100298342A1 (en) * 2006-09-07 2010-11-25 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease
TW201006816A (en) * 2008-05-15 2010-02-16 Organon Nv Hexafluoroisopropanol derivatives
JP2012526136A (ja) * 2009-05-07 2012-10-25 メルク・シャープ・エンド・ドーム・コーポレイション 抗糖尿病化合物として有用な置換スピロ環式アミン
JPWO2011142359A1 (ja) * 2010-05-10 2013-07-22 日産化学工業株式会社 スピロ化合物及びアディポネクチン受容体活性化薬
AU2011256444B2 (en) * 2010-05-18 2014-07-10 Merck Sharp & Dohme Corp. Spiro isoxazoline compounds as SSTR5 antagonists
WO2012024183A1 (en) * 2010-08-18 2012-02-23 Merck Sharp & Dohme Corp. Spiroxazolidinone compounds
TW201712012A (zh) * 2015-06-16 2017-04-01 美國禮來大藥廠 ２－側氧基－１，３，８－三氮雜螺［４．５］癸－３－基羧酸衍生物
WO2018024602A1 (en) * 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes

Similar Documents

Publication Publication Date Title
JP2023516235A5 (https=)
US20130261108A1 (en) Compositions and methods for modulating farnesoid x receptors
CN103502226B (zh) 用于cetp抑制剂的环烯基芳基衍生物
JP2022512482A5 (https=)
ES2539256T3 (es) Compuestos de 3-fenil-1,2,4-oxadiazol sustituidos
US20140039007A1 (en) Compositions and methods for modulating farnesoid x receptors
EA030430B1 (ru) Композиции и способы модуляции фарнезоидных х-рецепторов
WO2007106469A2 (en) Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
JP2007502264A5 (https=)
TW200831511A (en) Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
JP2015533782A (ja) スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用
TW200804266A (en) Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders
CN103237795B (zh) 经取代的噁二唑化合物及其作为s1p1激动剂的用途
CN111164072A (zh) β-羟基杂环胺及其在治疗高糖血症中的用途
CN103298807A (zh) 作为用于治疗自身免疫性疾病和血管疾病的s1p1激动剂的杂环化合物
IL290882B1 (en) Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations
DK2697219T3 (en) NEW PIPERIDINYLMONOCARBOXYLSYRER AS S1P1 receptor agonists
JP2004269469A (ja) ピリミジン誘導体又はその塩
CN106660988A (zh) 经取代的双环二氢嘧啶酮及其作为嗜中性粒细胞弹性蛋白酶活性的抑制剂的用途
RU2627361C2 (ru) Биарил- или гетероциклические биарилзамещенные производные циклогексена в качестве ингибиторов сетр
JPWO2001036402A1 (ja) 新規な２−（ｎ−シアノイミノ）チアゾリジン−４−オン誘導体
JP2020521775A5 (https=)
JP2022554330A5 (https=)
JP2022542613A (ja) ヒトａｔｇｌの阻害剤
TW202417426A (zh) 三氮唑類化合物及其作為lpar1拮抗劑的用途